Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013-2017

被引：14
作者：
Shimbashi, Reiko [1 ,2 ]
Suzuki, Motoi [1 ,2 ]
Chang, Bin [1 ]
Watanabe, Hiroshi [3 ]
Tanabe, Yoshinari [4 ]
Kuronuma, Koji [5 ]
Oshima, Kengo [2 ]
Maruyama, Takaya [6 ]
Takeda, Hiroaki [7 ]
Kasahara, Kei [8 ]
Fujita, Jiro [9 ]
Nishi, Junichiro [10 ]
Kubota, Tetsuya [11 ]
Tanaka-Taya, Keiko [1 ]
Matsui, Tamano [1 ]
Sunagawa, Tomimasa [1 ]
Oishi, Kazunori [1 ,12 ]
机构：
[1] Natl Inst Infect Dis, Tokyo, Japan
[2] Tohoku Univ, Grad Sch Med, Sendai, Miyagi, Japan
[3] Kurume Univ, Sch Med, Fukuoka, Japan
[4] Niigata Prefectural Shibata Hosp, Niigata, Japan
[5] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan
[6] Natl Hosp Org Mie Natl Hosp, Tsu, Mie, Japan
[7] Yamagata Saisei Hosp, Yamagata, Japan
[8] Nara Med Univ, Nara, Japan
[9] Univ Ryukyus, Grad Sch Med, Nishihara, Okinawa, Japan
[10] Kagoshima Univ, Grad Sch Med & Dent Sci, Kagoshima, Japan
[11] Kochi Univ, Kochi Med Sch, Kochi, Japan
[12] Toyama Inst Hlth, Toyama, Japan
来源：
EMERGING INFECTIOUS DISEASES | 2020年 / 26卷 / 10期
关键词：
PNEUMONIAE SEROTYPE 12F; CONJUGATE VACCINE; POPULATION; IMPACT; OLDER; SPAIN;
D O I：
10.3201/eid2610.191531
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The decline in the proportion of pneumococcal conjugate vaccine (PCV)-covered serotypes among adult invasive pneumococcal disease (IPD) patients might change the overall effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) because its effectiveness differs according to serotype. Using the indirect cohort method, we calculated the effectiveness of PPSV23 against IPD among adults in Japan to assess the impact of the national pediatric PCV program. Clinical and epidemiologic information and pneumococcal isolates were collected from IPD patients >= 20 years of age through enhanced IPD surveillance during April 2013-December 2017. Adjusted effectiveness against PPSV23-serotype IPD was 42.2%. Despite a substantial decline in the proportion of 13-valent PCV serotypes during the study period (45% to 31%), the change in effectiveness for PPSV23-serotype IPD was limited (47.1% to 39.3%) and only marginal in the elderly population (39.9% to 39.4%). The pediatric PCV program had limited impact on PPSV23 effectiveness against IPD in adults.
引用
收藏
页码：2378 / 2386
页数：9
相关论文
共 50 条
  • [41] Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) in Preventing Community-Acquired Pneumonia in Adults: A Population-Based Cohort Study
    Serra-Prat, Mateu
    Bolibar, Ignasi
    Palomera, Elisabet
    Lavado, Angel
    Almirall, Jordi
    VACCINES, 2024, 12 (09)
  • [42] Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan
    Nakashima, Kei
    Suzuki, Kanzo
    Aoshima, Masahiro
    Murabata, Mayumi
    Kondo, Kyoko
    Ohfuji, Satoko
    Fukushima, Wakaba
    Maeda, Akiko
    Hirota, Yoshio
    Pneumonia Elderly People Study Grp
    VACCINE, 2022, 40 (46) : 6589 - 6598
  • [43] Immunogenicity and safety of concomitant MF59-adjuvanted influenza vaccine and 23-valent pneumococcal polysaccharide vaccine administration in older adults
    Song, Joon Young
    Cheong, Hee Jin
    Tsai, T. F.
    Chang, Hyun-ah
    Choi, Min Joo
    Jeon, Ji Ho
    Kang, Seong Hee
    Jeong, Eun Ju
    Noh, Ji Yun
    Kim, Woo Joo
    VACCINE, 2015, 33 (36) : 4647 - 4652
  • [44] Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain
    Dominguez, Angela
    Soldevila, Nuria
    Toledo, Diana
    Torner, Nuria
    Force, Luis
    Jose Perez, Maria
    Martin, Vicente
    Rodriguez-Rojas, Lourdes
    Astray, Jenaro
    Egurrola, Mikel
    Sanz, Francisco
    Castilla, Jesus
    PLOS ONE, 2017, 12 (02):
  • [45] Pneumococcal vaccine uptake and vaccine effectiveness in older adults with invasive pneumococcal disease in Germany: A retrospective cohort study
    Perniciaro, Stephanie
    van der Linden, Mark
    LANCET REGIONAL HEALTH-EUROPE, 2021, 7
  • [46] Evaluation of effectiveness, safety and cost-benefit of the 23-valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
    Zou, Xiaobai
    He, Jianmei
    Zheng, Jun
    Liang, Mengran
    Gao, Jinjin
    Huang, Jianwen
    Jiang, Yang
    Jiang, Yonglin
    Chen, Xi
    VACCINE, 2022, 40 (01) : 37 - 42
  • [47] A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine
    Laratta, C. R.
    Williams, K.
    Vethanayagam, D.
    Ulanova, M.
    Vliagoftis, H.
    ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2017, 13
  • [48] Reply to letter: Retrospective cost-effectiveness of the 23-valent pneumococcal polysaccharide vaccination program in Australia
    Newall, A. T.
    Wood, J. G.
    Chen, C.
    McIntyre, P.
    Beutels, P.
    VACCINE, 2019, 37 (52) : 7534 - 7534
  • [49] Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine
    Liang, Qi
    Li, Gui-Fan
    Zhu, Feng-Cai
    EXPERT REVIEW OF VACCINES, 2016, 15 (11) : 1351 - 1359
  • [50] Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial
    Marechal, Celine
    Lal, Himal
    Poder, Airi
    Ferguson, Murdo
    Enweonye, Igwebuike
    Heineman, Thomas C.
    Herve, Caroline
    Rheault, Paul
    Talli, Jaak
    Wauters, Dominique
    Oostvogels, Lidia
    VACCINE, 2018, 36 (29) : 4278 - 4286
12345